Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to establish a joint venture (JV) with Israeli company Insightec. The new JV will concentrate on the commercial development and clinical application of a magnetic resonance guided focused ultrasound (MRgFUS) brain therapy system in China, targeting patients with Parkinson’s disease and idiopathic tremor to improve their quality of life. The company also intends to partner with various medical centers across China to explore further applications of the technology in the treatment of neurological disorders.
The product integrates focused ultrasound with magnetic resonance imaging (MRI) to pinpoint treatment targets accurately using MRI and employs high-intensity focused ultrasound to ablate lesions, thereby achieving therapeutic outcomes. Globally, it has treated over 10,000 patients suffering from Parkinson’s disease and idiopathic tremor. In 2021, the product received marketing approval in China for the treatment of drug-resistant idiopathic tremor and Parkinson’s disease where tremor is the predominant symptom.- Flcube.com
